On September 5, 2019 Schrödinger reported the expansion of its multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the collaboration’s most advanced program (Press release, Schrodinger, SEP 5, 2019, View Source [SID1234539316]). The expansion increases the potential number of drug discovery programs that can be initiated under the collaboration and increases the cumulative value of potential future milestone payments that Schrödinger is eligible to receive per program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the collaboration, Schrödinger’s discovery and translational team deploys the company’s highly advanced physics-based computational platform to discover novel, differentiated compounds. Schrödinger is taking the lead role in discovery and pharmacological characterization of the molecules, and has access to Takeda’s structural biology and therapeutic area expertise.
"We are thrilled to extend our partnership with Takeda," said Karen Akinsanya, Ph.D., Schrödinger’s Chief Biomedical Scientist. "This successful collaboration shows what is possible when drug discovery researchers have access to the full power of Schrödinger’s computational platform and are able to accelerate molecules into key assays and disease models. We’re proud of our ability to deliver to Takeda advanced candidates to address challenging unmet medical needs."
"Schrödinger has been a strong strategic partner for Takeda and we have seen great progress on the programs loaded thus far," said David Weitz, Head of Takeda California and Global Research Externalization. "This mutually beneficial partnership capitalizes on the complementary strengths of both companies as well as the healthy, supportive spirit of collaboration that has been cultivated between the teams."
Schrödinger has established partnerships with leading biotech and pharmaceutical companies around the world. The company’s pipeline includes both partnered and internal ongoing programs in indications such as fibrosis, oncology, diabetes, and inflammation.